Uniting human and machine intelligence for drug discovery in CKD

Chronic Kidney Disease is a complex condition with limited treatment options. A collaboration between AstraZeneca and BenevolentAI is leveraging scientific expertise and machine learning to develop novel targets to possibly treat CKD in the future. Listen to the experts from AstraZeneca and BenevolentAI talk about their collaboration in CKD, the approaches to leveraging vast datasets and how knowledge graphs are unlocking new targets and underlying drivers of this complex disease.
Read more...

;